Angiotensin II administration to rats during 6 weeks causes decreased activity of catalase and glutathione peroxidase in renal cortex. Rats show mild hypertension, subclinical signs of renal injury, increased glomerular expression of desmin, glomerular and interstitial expression of α-smooth muscle actin and an increased number of ED-1-positive cells in glomeruli. An inverse correlation exists between catalase activity and glomerular α-smooth muscle actin expression and between glutathione peroxidase activity and glomerular desmin expression. The decrease of antioxidant enzyme activity, early after angiotensin II administration, might be an important initiating factor in the complex process leading eventually to renal sclerosis by reduction of reactive oxygen intermediate breakdown. The significant relationship between markers of sclerosis and some antioxidant enzyme activities suggests either a causative link or a common triggering factor.

Keywords:
Renal failure, Antioxidant enzymes, Angiotensin II, Desmin, α-Smooth muscle actin
1.
El Nahas AM, Muchaneta-Kubara EC, Essawy M, Soylemezoglu O: Renal fibrosis: Insights into pathogenesis and treatment. Int J Cell Biol 1997;29:55–62.
2.
Lafayette RA, Mayer G, Park SK, Meyer TW: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992;90:766–771.
3.
Reams G, Bauer JH: Enalapril in subjects with renal disease. J Hypertens 1986;4:S417–S419.
4.
Keane WF, Anderson S, Aurell M, de Zeeuw D, Narins RG, Povar G: Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Ann Intern Med 1989;111:503–516.
5.
Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577–581.
6.
Verbeelen DL, Peeters P, Vanden Houte K, De Craemer D, Van den Branden C: Enalapril increases antioxidant enzyme activity in renal cortical tissue of 5/6 nephrectomized rats. Nephron 1998;80:214–219.
7.
Ketteler M, Noble NA, Border WA: Transforming growth factor-β and angiotensin II: The missing link from glomerular hyperfiltration to glomerulosclerosis? Annu Rev Physiol 1995;57:279–295.
8.
Border WA, Ruoslahti E: Transforming growth factor-β in disease: The dark side of tissue repair. J Clin Invest 1992;90:1–7.
9.
Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA: Expression of transforming growth factor-β is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993;90:1814–1818.
10.
Yoshioka K, Takemura T, Murakami K, Okada M, Hino S: Transforming growth factor-β protein and m-RNA in glomeruli in normal and diseased human kidneys. Lab Invest 1993;68:154–163.
11.
Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431–2437.
12.
Weiss RH, Ramirez A: TGF-β- and angiotensin-II-induced mesangial matrix protein secretion is mediated by protein kinase C. Nephrol Dial Transplant 1998;13:2804–2813.
13.
Huwiler A, van Rossum G, Wartmann M, Pfeilschifter J: Angiotensin II stimulation of the stress-activated protein kinases in renal mesangial cells is mediated by the angiotensin AT1 receptor subtype. Eur J Pharmacol 1998;343:297–302.
14.
Studer RK, Craven PA, DeRubertis FR: Antioxidant inhibition of protein kinase C-signaled increases in transforming growth factor-beta in mesangial cells. Metab Clin Exp 1997;46:918–925.
15.
Kuemmerle NB, Brandt RB, Chan W, Krieg RJ, Chan JC: Inhibition of transforming growth factor β1 induction by dietary vitamin E in unilateral ureteral obstruction in rats. Biochem Mol Med 1997;61:82–86.
16.
Van den Branden C, Verelst R, Vamecq J, Vanden Houte K, Verbeelen D: Effect of vitamin E on antioxidant enzymes, lipid peroxidation products and glomerulosclerosis in rat remnant kidney. Nephron 1997;76:77–81.
17.
Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Prizl P, Floege J, Schwartz SM: Renal injury from angiotensin II-mediated hypertension. Hypertension 1992;19:464–474.
18.
Muchaneta-Kubara EC, El Nahas AM: Myofibroblast phenotypes expression in experimental scarring. Nephrol Dial Transplant 1997;12:904–915.
19.
Holthöfer H, Sainio K, Miettinen A: The glomerular mesangium: Studies of its developmental origin and markers in vivo and vitro. APMIS 1995;103:354–366.
20.
Spooner G, Muller-Beckmann B, Martin U: Blood pressure recording in rats: Pitfalls and problems; in Gretz N, Strauch M (eds): Experimental and Genetic Rat Models of Chronic Renal Failure. Basel, Karger, 1993, pp 319–330.
21.
Lopez De Leon A, Rojkind M: A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J Histochem Cytochem 1985;33:737–743.
22.
Claeys A, Cornelis A, Kerckaert I, Coen H, Zukowski F, Smets G, Roels F: Fully automated measurements by light microscopy of tissue sections using a cellular assay computer. Gegenbaurs Morphol Jahrb 1989; 135 : 83–90.
23.
Marklund S, Marklund G: Involvement of the superoxide anion radical in the autooxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 1974;47:469–474.
24.
Baudhuin P: Isolation of rat liver peroxisomes. Methods Enzymol 1974;31:358–368.
25.
Carmagnol F, Sinet P, Jerome H: Selenium dependent and non-selenium dependent glutathione peroxidases in human tissue extracts. Biochim Biophys Acta 1983;759:49–57.
26.
Griffin SA, Brown WCB, Macpherson F, McGrath JC, Wilson VG, Korsgaard N, Mulvany MJ, Lever AF: Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 1991;17:626–635.
27.
Border WA, Noble NA: Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 1998;31:181–188.
28.
Miller P, Rennke HG, Meyer TW: Glomerular hypertrophy accelerates hypertensive glomerular injury in rats. Am J Physiol 1991;30:F459–F465.
29.
Beukers JJB, Hoedemaker PJ, Weening JJ: Pharmacological and dietary intervention in experimental models of chronic renal disease. Contrib Nephrol 1988;60:101–115.
30.
Stamenkovic I, Skalli O, Gabiani G: Distribution of intermediate filament proteins in normal and diseased human glomeruli. Am J Pathol 1986;125:465–475.
31.
Van den Branden C, Ceyssens B, De Craemer D, De Bleser P, Hellemans K, Geerts A, Verbeelen D: Antioxidant enzyme gene expression in rats with remnant kidney induced chronic renal failure. Exp Nephrol 2000;8:91–96.
32.
Wu LL, Yang N, Ror CJ, Cooper ME, Gilbert RE, Atkins RC, Lan HY: Macrophage and myofibroblast proliferation in remnant kidney: Role of angiotensin II. Kidney Int 1997;52(suppl 63):S221–S225.
33.
Boyce NW, Tipping PG, Holdsworth SR: Glomerular macrophages produce reactive oxygen species in experimental glomerulonephritis. Kidney Int 1989;35:778–782.
34.
Van den Branden C, Vamecq J, Verbeelen D, Roels F: In vivo hydrogen peroxide production in rat remnant kidney. Ren Physiol Biochem 1994;17:240–245.
35.
Gwinner G, Landmesse U, Brandes RP, Kubat B, Plasger J, Eberhard O, Koch KM, Olbricht CJ: Reactive oxygen species and antioxidant defense in puromycin aminonucleoside glomerulopathy. J Am Soc Nephrol 1997;8:1722–1731.
36.
Kavutcu M, Canbolat O, Oztürk S, Olcay E, Ulutepe S, Ekinci C, Gökhun, Durak I: Reduced enzymatic antioxidant defense mechanism in kidney tissues from gentamicin-treated guinea pigs: Effects of vitamins E and C. Nephron 1996;72:269–274.
37.
Durak I, Karabacak HI, Büyükkoçak S, Burak Cimen MY, Kaçmaz M, Omeroglu E, Oztürk HS: Impaired antioxidant defense system in the kidney tissues from rabbits treated with cyclosporine. Protective effects of vitamins E and C. Nephron 1998;78:207–211.
38.
Sechi LA, Ceriello A, Griffin CA, Catena C, Amstad P, Schambelan M, Bartoli E: Renal antioxidant enzyme mRNA levels are increased in rats with experimental diabetes mellitus. Diabetologia 1997;40:23–29.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.